Form 4: CEO Kevin Coop Boosts Stake in Definitive Healthcare

Definitive Healthcare CEO Kevin Coop acquired over 1.7 million restricted stock units, increasing his direct beneficial ownership.

Summary

• Kevin Coop, Chief Executive Officer and Director of Definitive Healthcare Corp. (DH), acquired 1,735,437 shares of Class A Common Stock.
• These shares are in the form of Restricted Stock Units (RSUs), each representing a contingent right to receive one share of the Issuer's Class A Common Stock.
• The RSUs will vest 25% on March 1, 2027, followed by 6.25% every three months thereafter over the subsequent three years.
• Vesting is subject to Mr. Coop's continued service with Definitive Healthcare Corp. through each vesting date.
• Following this transaction, Mr. Coop directly beneficially owns 5,291,989 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as the CEO's increased equity stake through a significant RSU grant aligns his interests with long-term shareholder value and signals confidence in the company's future.

Positives

• CEO Kevin Coop's acquisition of 1,735,437 Restricted Stock Units (RSUs) demonstrates increased alignment of management interests with shareholder value.
• The significant grant of RSUs, subject to a multi-year vesting schedule, indicates a long-term commitment from the CEO to the company's performance and growth.

Risks

• The vesting of the Restricted Stock Units (RSUs) is subject to Kevin Coop's continued service with Definitive Healthcare Corp., meaning the shares could be forfeited if his employment terminates before vesting dates.

Future Outlook

The multi-year vesting schedule for the RSUs, extending beyond March 1, 2027, implies an expectation of continued service from the CEO and a long-term strategic horizon for the company.

Industry Context

StockSavvy.ai notes that insider purchases, especially by a CEO, are often viewed positively by the market as they signal confidence in the company's future prospects, particularly in the healthcare data and analytics sector where long-term strategic vision is crucial.

Comparison to Industry Standards

• StockSavvy.ai observes that equity compensation, particularly through Restricted Stock Units with multi-year vesting, is a standard practice across the technology and healthcare sectors to incentivize long-term executive retention and performance.
• Similar RSU grants with service-based vesting schedules are common at companies like IQVIA Holdings Inc. (IQV) or Veeva Systems Inc. (VEEV), which operate in related data and software domains, aiming to align executive interests with sustained shareholder value creation.

Stakeholder Impact

• Shareholders: Potentially positive, as increased insider ownership can signal confidence and align management incentives with shareholder returns.
• Employees: No direct impact mentioned, but a stable leadership team with long-term incentives can foster a more secure work environment.

Next Steps

• Vesting of 25% of the Restricted Stock Units on March 1, 2027.
• Subsequent vesting of 6.25% of RSUs every three months over the following three years, subject to continued service.

Key Dates

Recommendation

The grant of Restricted Stock Units to the CEO, while a positive signal of long-term commitment and alignment with shareholder interests, is a form of compensation rather than an open market purchase. It reinforces confidence in the current management and strategy but does not present new fundamental information that would drastically alter the investment thesis, thus supporting a 'hold' recommendation for existing investors and a neutral stance for new ones pending further operational updates.

Keywords

Definitive Healthcare, DH, Kevin Coop, Insider Trading, Form 4, Restricted Stock Units, RSUs, CEO, Director, Stock Ownership, Equity Compensation